Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.779 USD | +9.00% | +13.91% | +11.18% |
Apr. 25 | OncoCyte Corporation announced that it has received $15.807655 million in funding | CI |
Apr. 16 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
Business Summary
Number of employees: 45
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Tests
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +56.89% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
61.0
%
| 1 | 76.5 % | 1 | 61.0 % | +25.24% |
Non-United States
39.0
%
| 0 | 23.5 % | 1 | 39.0 % | +160.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
James Liu
DFI | Director of Finance/CFO | 29 | 21-06-30 |
Yuh-Min Chiang
CTO | Chief Tech/Sci/R&D Officer | - | 21-08-31 |
Ekkehard Schütz
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
Peter Hong
LAW | General Counsel | - | - |
Padma Sundar
PRN | Corporate Officer/Principal | - | 19-05-21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Last
BRD | Director/Board Member | 64 | 15-12-22 |
Louis Silverman
BRD | Director/Board Member | 65 | 22-11-29 |
Andy Arno
CHM | Chairman | 64 | 15-05-31 |
Joshua Riggs
CEO | Chief Executive Officer | 42 | 20-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,364,637 | 6,565,256 ( 49.12 %) | 0 | 49.12 % |
Stock B | 0 | 5,000 | 0 | 0 |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.18% | 34.08M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- OCX Stock
- Company OncoCyte Corporation